Associated Papers
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
41593049 (PubMed )
Supplement: 41389_2026_599_MOESM2_ESM.xlsx › Supplementary_Table_10
Genomic alterations in the WNT/β-catenin pathway and resistance of colorectal cancer cells to pathway-targeting therapies.
Voutsadakis IA
Exploration of Targeted Anti-tumor Therapy, 2025
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Hoyer K et al.
Ebiomedicine, 2021
33862582 (PubMed )
Supplement: mmc3.xlsx › S5
The most common RNF43 mutant G659Vfs*41 is fully functional in inhibiting Wnt signaling and unlikely to play a role in tumorigenesis.
Tu J et al.
Scientific Reports, 2019
31811196 (PubMed )
Supplement: 41598_2019_54931_MOESM1_ESM.pdf
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Milewska M et al.
Therapeutic Advances in Medical Oncology, 2018
Select a paper to view details